SUBSCRIBE
SUBSCRIBE
News   Drug Development

GlaxoSmithKline’s Avandia Linked with Heart Risk Again

March 18, 2011 | 
1 min read
Pharma Times -- GlaxoSmithKline's fallen diabetes drug Avandia has taken another hit after research in the British Medical Journal added further weight to evidence that the drug could put patients at an increased risk from heart disease.
Clinical research Postmarket research
GlaxoSmithKline
MORE ON THIS TOPIC
vector illustration arrows miss the target board, concept of lost in focus, failure, fail, mistake
Alzheimer’s
Prothena’s Alzheimer’s Drug Comes With Familiar Side Effect in Phase I Test
August 28, 2025
 · 
2 min read
 · 
Annalee Armstrong
IN PARTNERSHIP WITH TRUVETA
Webinar: AI for Faster, More Precise Real-World Research: Extracting Clinical Notes Data at Scale
August 27, 2025
 · 
1 min read
 · 
BioSpace Insights
A pit crew working on a race car
Regulatory
The US Is Losing Its Biopharma Edge, Writes Former FDA Commissioner
August 27, 2025
 · 
3 min read
 · 
Dan Samorodnitsky
Contemporary art collage of target and hands with the megaphone on a ue background with copy space. Concept of reaching a goal and spreading.
Rare diseases
Regeneron Eyes 2026 Filing for siRNA Myasthenia Gravis Drug After Phase III Win
August 27, 2025
 · 
2 min read
 · 
Tristan Manalac